Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects

NCT02618967 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02618967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02618967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2016
Completion date
December 3, 2018
Enrollment
56 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus